• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Guardant, Illumina Resolve Litigation Issues Amid Renewed Cancer Research Partnership


Agreement includes request to dismiss pending lawsuit.

Lawyer explained to the client about the law that must be brought against the court case. Image Credit: Adobe Stock Images/wutzkoh

Image Credit: Adobe Stock Images/wutzkoh

Guardant Health, a precision oncology organization, and Illumina, a biotechnology company, have announced an agreement to end a legal battle between the two. As part of a new three-year deal, the companies have issued a joint request to dismiss with prejudice the pending litigation, including any allegations related to the subject intellectual property. Furthermore, the deal continues their long-standing commercial relationship by agreeing to collaborate on the sharing of specimen samples to advance cancer research.

“Both companies are deeply committed to our collaboration to help patients and conquer cancer,” said Chris Freeman, chief commercial officer, Guardant, in a company press release. “This agreement supports getting our transformative technologies to even more patients globally, while strengthening our long-standing and valued partnership with Illumina.”

Reference: Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research. Guardant. August 1, 2023. Accessed August 2, 2023. https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-resolves-pending-litigation-with-Illumina-and-enters-into-new-agreement-to-advance-long-term-commercial-partnership-and-cancer-research/default.aspx

Related Videos
Related Content